A5080522124- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Multiple Sclerosis Research Studies
- Advanced Neuroimaging Techniques and Applications
- Neurological Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Parkinson's Disease Mechanisms and Treatments
- Functional Brain Connectivity Studies
- Neurogenesis and neuroplasticity mechanisms
- Acute Ischemic Stroke Management
- RNA regulation and disease
- Brain Tumor Detection and Classification
- Health Systems, Economic Evaluations, Quality of Life
- Neurological disorders and treatments
- Advanced MRI Techniques and Applications
- Cerebrovascular and Carotid Artery Diseases
- Genetic Neurodegenerative Diseases
- Intensive Care Unit Cognitive Disorders
- Botulinum Toxin and Related Neurological Disorders
- Neurosurgical Procedures and Complications
- Neurological and metabolic disorders
- Vestibular and auditory disorders
- Cholinesterase and Neurodegenerative Diseases
- Genomics and Rare Diseases
- Health, Environment, Cognitive Aging
Institut des Maladies Neurodégénératives
2019-2025
Université de Bordeaux
2016-2025
Centre National de la Recherche Scientifique
2012-2025
Centre Hospitalier Universitaire de Bordeaux
2018-2025
Hôpital Pellegrin
2020-2024
Neurocentre Magendie
2015-2024
Inserm
2012-2024
Sorbonne Université
2016-2024
Bordeaux Population Health
2024
Assistance Publique – Hôpitaux de Paris
2016-2024
The chronological progression of brain atrophy over decades, from pre-symptomatic to dementia stages, has never been formally depicted in Alzheimer's disease. This is mainly due the lack cohorts with long enough MRI follow-ups cognitively unimpaired young participants at baseline. To describe a spatiotemporal staging disease whole-brain level, we built extrapolated lifetime volumetric models healthy and structures by combining multiple large-scale databases (n = 3512 quality controlled 9...
Background and purpose Few studies have investigated the differences in cognitive skills between three subtypes of multiple sclerosis ( MS ) they confounded course disease with duration physical disability. Moreover, were not population based. Methods This was a retrospective analysis testing from database French programme for care. The pattern frequency impairment secondary progressive SP ), primary PP late relapsing−remitting LRR , more than 10 years) compared. Results A total 101 patients...
Blood biomarkers for Alzheimer disease (AD) have consistently proven to be associated with CSF or PET and effectively discriminate AD from other neurodegenerative diseases. Our aim was test their utility in clinical practice, a multicentric unselected prospective cohort where patients presented large spectrum of cognitive deficits complaints. The MEMENTO enrolled 2,323 outpatients subjective complaint (SCC) mild impairment (MCI) consulting 26 French memory clinics. Participants had...
To assess the likely pathogenic/pathogenic (LP/P) variants rates in Mendelian dementia genes and moderate-to-strong risk factors patients with Alzheimer disease (AD). We included 700 a prospective study performed exome sequencing. A panel of 28 6 risk-factor was interpreted returned to patients. built framework for variant interpretation gradation assessed detection among early-onset AD (EOAD, age onset (AOO) ≤65 years, n = 608) depending on AOO pedigree structure late-onset (66 < 75, 92)....
à la diffusion de documents scientifiques niveau recherche, publiés ou non, émanant des établissements d'enseignement et recherche français étrangers, laboratoires publics privés.
Abstract INTRODUCTION The three clinical variants of frontotemporal dementia (behavioral variant [bvFTD], semantic dementia, and progressive non‐fluent aphasia [PNFA]) are likely to develop over decades, from the preclinical stage death. METHODS To describe long‐term chronological anatomical progression FTD variants, we built lifespan brain charts normal aging by combining 8022 quality‐controlled MRIs multiple large‐scale data‐bases, including 107 bvFTD, 44 38 PNFA. RESULTS We report in this...
This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis downstream biomarkers to examine whether antimyeloid immunotherapy changes course early Alzheimer disease.
We investigated whether diffusion tensor imaging (DTI) could reveal early hippocampal damage and clinically relevant correlates of memory impairment in persons with isolated syndrome (CIS) suggestive multiple sclerosis (MS).A total 37 CIS, 32 MS 36 controls prospectively included from 2011 to 2014 were tested for cognitive performances scanned 3T-magnetic resonance (MRI) assess volumetric DTI changes within the hippocampus, whole brain volume T2-lesion load.While there was no atrophy CIS...
<h3>Background</h3> Cerebellar damage has been implicated in information processing speed (IPS) impairment associated with multiple sclerosis (MS) that might result from functional disconnection the frontocerebellar loop. Structural alterations individual posterior lobules, which cognitive functioning seems preponderant, are still unknown. Our aim was to investigate impact of grey matter (GM) volume lobules VI VIIIb on IPS persons clinically isolated syndrome (PwCIS), MS (PwMS) and healthy...
Whether hippocampal subfields are differentially vulnerable at the earliest stages of multiple sclerosis (MS) and how this impacts memory performance is a current topic debate.We prospectively included 56 persons with clinically isolated syndrome (CIS) suggestive MS in 1-year longitudinal study, together 55 matched healthy controls baseline. Participants were tested for scanned 3 T MRI to assess volume 5 distinct using automatic segmentation techniques.At baseline, CA4/dentate gyrus was only...
Memory impairment is one of the disabling manifestations multiple sclerosis (MS) possibly present from early stages disease and for which there no specific treatment. Hippocampal synaptic dysfunction dendritic loss, associated with microglial activation, can underlie memory deficits, yet molecular mechanisms driving such hippocampal neurodegeneration need to be elucidated. In early-stage experimental autoimmune encephalomyelitis (EAE) female mice, we assessed expression level molecules...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy...
Abstract Brain charts for the human lifespan have been recently proposed to build dynamic models of brain anatomy in normal aging and various neurological conditions. They offer new possibilities quantify neuroanatomical changes from preclinical stages death, where longitudinal MRI data are not available. In this study, we used model progression atrophy progressive supranuclear palsy—Richardson syndrome. We combined multiple datasets (n = 8170 quality controlled healthy subjects 22 cohorts...
Elevated levels of Alzheimer disease (AD) blood-based biomarkers are associated with accelerated cognitive decline. However, their distinct relationships specific and functional domains require further investigation. We aimed at estimating the associations between AD trajectories over a 5-year follow-up period.
Progressive supranuclear palsy is a primary tauopathy affecting both neurons and glia responsible for motor cognitive symptoms. Recently, it has been suggested that progressive may spread in the brain from cell to 'prion-like' manner. However, direct experimental evidence of this phenomenon, its consequences on functions, still lacking primates. In study, we first derived sarkosyl-insoluble tau fractions post-mortem brains patients with palsy. We also isolated same fraction age-matched...